Mediwound Ltd - Asset Resilience Ratio
Mediwound Ltd (MDWD) has an Asset Resilience Ratio of 46.83% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check MDWD strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Mediwound Ltd's Asset Resilience Ratio has changed over time. See MDWD equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Mediwound Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MDWD market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $31.38 Million | 46.83% |
| Total Liquid Assets | $31.38 Million | 46.83% |
Asset Resilience Insights
- Very High Liquidity: Mediwound Ltd maintains exceptional liquid asset reserves at 46.83% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Mediwound Ltd Industry Peers by Asset Resilience Ratio
Compare Mediwound Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
|
Concord Biotech Limited
NSE:CONCORDBIO |
Biotechnology | 18.00% |
|
Pharming Group NV
AS:PHARM |
Biotechnology | 7.13% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653 |
Biotechnology | 56.48% |
Annual Asset Resilience Ratio for Mediwound Ltd (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Mediwound Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 46.27% | $34.01 Million | $73.50 Million | +1.62pp |
| 2023-12-31 | 44.65% | $29.68 Million | $66.46 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $50.02 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $19.74 Million | -- |
| 2020-12-31 | 12.95% | $4.02 Million | $31.07 Million | -41.34pp |
| 2019-12-31 | 54.29% | $22.04 Million | $40.59 Million | +6.33pp |
| 2018-12-31 | 47.96% | $16.92 Million | $35.28 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $44.13 Million | -- |
| 2016-12-31 | 3.25% | $1.16 Million | $35.76 Million | -2.97pp |
| 2015-12-31 | 6.22% | $3.27 Million | $52.52 Million | -49.22pp |
| 2014-12-31 | 55.44% | $39.43 Million | $71.12 Million | +38.58pp |
| 2013-12-31 | 16.86% | $2.50 Million | $14.83 Million | -- |
About Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more